FEP633

FEP633 is a small molecule prodrug developed by PRISM BioLab as a novel inhibitor targeting the interaction between eukaryotic translation initiation factor 4E (eIF4E) and eukaryotic translation initiation factor 4 gamma 1 (eIF4G1). This interaction is critical for cap-dependent mRNA translation, which is often upregulated in cancer. FEP633 acts as a binding inhibitor of the eIF4E/eIF4G1 complex, thereby suppressing oncogenic protein synthesis. It is designed as a prodrug of FEP600, which mimics the action of the natural repressor protein 4E-BP1 to block this pathway. Preclinical studies have shown that its active form can be more efficacious than cisplatin in patient-derived xenograft models of urothelial carcinoma[2][1]. The drug is being developed primarily for neoplasms such as bladder cancer and other urogenital cancers[2][1].